Navigation Links
AspenBio Pharma to Provide Shareholders with Business Update
Date:8/8/2012

CASTLE ROCK, Colo., Aug. 8, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, announced that it will begin hosting regular conference calls to provide its investors and the broader investment and medical communities with timely updates on the Company's business and anticipated milestones.  AspenBio's senior management will host a conference call and live audio webcast on Wednesday, August 15, 2012, at 5:00 p.m. ET to discuss recent activities and upcoming plans for the clinical development and potential commercialization of AppyScore™.  

Interested participants and investors may access the conference call by dialing (800) 860-2442 (U.S./Canada) or (412) 858-4600 (international).  An audio webcast will be accessible via the Investors Relations section of the AspenBio web site, www.aspenbiopharma.com.  

A telephonic replay of the call will be available for two weeks beginning at 8:00 p.m. ET on August 15, 2012.  Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10017298.  The webcast replay will remain available in the Investors Relations section of the AspenBio web site for 30 days.

About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its lead product, AppyScoreAppyScore is a unique blood-based test with projected high sensitivity and negative predictive value that is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management.  AppyScore is initially being developed for pediatric, adolescent and young adult patients with abdominal pain as this population is at the highest risk for appendicitis as well having the highest risk of the long-term health effects associated with CT imaging.  For more information, visit www.aspenbiopharma.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for AppyScore required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from AppyScore, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Final Prospectus filed on June 20, 2012.

For Investors & Media:
Joshua Drumm, PhD / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com

 


'/>"/>
SOURCE AspenBio Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AspenBio Pharma Executes Worldwide License Agreement for its Animal Health Assets
2. AspenBio Pharma Engages Tiberend Strategic Advisors as Investor and Public Relations Agency of Record
3. Cardinal Health Supports Future Pharmacists With Nearly $1 Million In Scholarships
4. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
6. Online Pharmacy Domain Policy Changes Announced by ICANN Registrar Internet.bs Corp.
7. Jazz Pharmaceuticals Announces Second Quarter 2012 Results
8. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
9. K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets
10. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
11. German-based Contract Research Organization Verum.de Opens US Office to Expand Clinical Study Services in Central and Eastern Europe for American Pharma and Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... SAN DIEGO , Jan. 14, 2017  Johnson & ... on behalf of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... 7, 2016, through October 31, 2016 (the "Class Period"). ... designs, manufactures, and markets orthopaedic reconstructive products, such as knee ... ...
(Date:1/13/2017)... NEW YORK , January 13, 2017 ... Equipment equities: Wright Medical Group N.V. (NASDAQ: WMGI ... MiMedx Group Inc. (NASDAQ: MDXG ), and NuVasive ... the Healthcare sector which fell back to a negative finish ... Health Care Index falling about 0.1%, while shares of health ...
(Date:1/13/2017)... MURRIETA, Calif. , Jan. 13, 2017  Alfalfa, cattle, ... COPAN Diagnostic,s new environmental sampling film , which emphasizes the ... video, released today, highlights how COPAN,s ... product that simplifies the surface sampling process in the wake ... . In addition, COPAN is expanding ...
Breaking Medicine Technology:
(Date:1/16/2017)... MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of the ... , This year’s influenza shot seems to be having no effect on keeping ... at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to ... treat, but to test for, as well. The money spent screening for and treating ... in the U.S. screen patients for cancer more than in any other country that ...
(Date:1/15/2017)... , ... January 15, 2017 , ... In this role, ... the United States for the asthma & allergy friendly mark. This certification program was ... test and identify consumer products to be more suitable for the 60+ million people ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow production ... said Christina Austin - CEO of Pixel Film Studios. , On Tour’s new ... style and animation of their slideshows. Place each slide on top of another slide ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... NJ is pleased to announce that it will be assisting HackensackUMC Mountainside with ... and Glen Ridge townships, servicing all surrounding towns. The firm will be working ...
Breaking Medicine News(10 mins):